A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
-
BUSINESS Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
-
ACADEMIA Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
-
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
-
REGULATORY Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
-
BUSINESS LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
-
BUSINESS Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
-
BUSINESS AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
-
ORGANIZATION PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair
March 12, 2014
-
REGULATORY Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
-
BUSINESS Pfizer Japan Logs 1.2% Sales Increase in FY2013
March 10, 2014
-
BUSINESS Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
-
ORGANIZATION FPMAJ Generic Guidelines Urge Makers to Create “Stable Supply” Officer Post
March 7, 2014
-
BUSINESS 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
-
BUSINESS New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
-
REGULATORY FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule
March 5, 2014
-
BUSINESS Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
-
BUSINESS Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
-
BUSINESS Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
-
ACADEMIA JAMS’s Newly Revised COI Management Guidelines Impose Stricter Rules
February 28, 2014
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…